New hope for aggressive breast cancer: personalized therapy shows promise
NCT ID NCT02810743
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase III trial tests whether personalized therapy can improve survival for people with high-risk BRCA1-like breast cancer. Participants receive either standard chemotherapy or a more intense regimen with stem cell rescue. The study aims to find a better way to treat this aggressive cancer type.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ddAC-CP-Olaparib and ddAC-mini CTC chemotherapy with stem cell rescue
What this could lead to
If successful, this could offer a more effective, personalized treatment for high-risk BRCA1-like breast cancer, potentially improving survival rates.
What could go wrong
This is a phase III trial but with only 174 participants, results may not apply to all patients. The intensified chemotherapy carries significant risks, including side effects from stem cell rescue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZVU
Amsterdam, 1081 HV, Netherlands
-
Antoni van Leeuwenhoek
Amsterdam, 1066 CX, Netherlands
-
Erasmus Medical Center Cancer Institute
Rotterdam, 3015CE, Netherlands
-
Hopital Tenon, University Marie-Curie
Paris, France
-
Institut Paoli Calmettes
Marseille, 13009, France
-
LUMC
Leiden, 2333 ZA, Netherlands
-
Maastricht University Medical Center
Maastricht, Netherlands
-
Medical spectrum Twente
Enschede, Overijssel, 7500 KA, Netherlands
-
Radboud UMC
Nijmegen, 6225GA, Netherlands
-
University Medical Center Groningen
Groningen, Netherlands
-
University Medical Center Utrecht
Utrecht, 3584CX, Netherlands